Side-by-side · Research reference

PT-141vsSNAP-8

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED13/41 cited

BHuman-MechanisticHUMAN-REVIEWED8/46 cited

PT-141

MC4R Agonist · FDA-Approved (HSDD)

1.75 mgPer doseVYLEESI (bremelanotide injecti 2019

Pre-sexTimingVYLEESI (bremelanotide injecti 2019

~2.7 hrHalf-lifeVYLEESI (bremelanotide injecti 2019

SQ · Abdomen / thigh · ≥45 min before sex

SNAP-8

Synthetic Octapeptide · Cosmetic Topical

TopicalRoute

8-AAPeptide length

SNAREPrimary target

Topical · Facial application · Twice daily

01Mechanism of Action

Parameter

PT-141

SNAP-8

Primary target

Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023 VYLEESI (bremelanotide injecti 2019

SNARE complex (SNAP-25 competitive binding site)

Pathway

MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023

Acetyl octapeptide-3 → SNARE complex disruption → Reduced vesicular fusion → Decreased acetylcholine release → Muscle relaxation

Downstream effect

Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015

Transient reduction in neuromuscular signal transmission, decreased muscle contraction amplitude, wrinkle depth reduction

Feedback intact?

—

N/A — topical cosmetic, no systemic endocrine axis

Origin

Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019

Synthetic peptide derived from N-terminal fragment of SNAP-25 protein (synaptosomal-associated protein 25 kDa)

Antibody development

—

02Dosage Protocols

Parameter

PT-141

SNAP-8

Standard dose

1.75 mg SQVYLEESI (bremelanotide injecti 2019

Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.

—

Frequency

PRN, max 8 doses / month

—

Lower / starter dose

1 mg (off-label)

—

Evidence basis

FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019 Clayton 2015

RCT, in vitro skin penetration studies

Duration

PRN; reassess if no benefit after 8 doses

—

Reconstitution

Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.

—

Timing

≥45 min before sexual activity

—

Half-life

~2.7 hrVYLEESI (bremelanotide injecti 2019

—

Typical concentration

—

2–10% in cosmetic formulationsLupin 2024 Raikou 2017

Commercial products typically use 5–10%.

Application frequency

—

Twice daily (morning and evening)Lupin 2024

Treatment duration

—

20–60 days for visible effectRaikou 2017

Skin microtopography improvements measured at 20-day intervals.

Formulation type

—

Oil-in-water emulsion, serum, cream

Application site

—

Facial skin — glabellar lines, crow's feet, forehead

Onset of effect

—

Visible reduction in wrinkle depth by day 20–28Raikou 2017

03Metabolic / Fat Loss Evidence

04Side Effects & Safety

Parameter

PT-141

SNAP-8

Nausea

Common (~40%); often transientVYLEESI (bremelanotide injecti 2019

—

Flushing

Common, transient

—

Injection site reaction

Erythema, mild pain

—

Headache

Common

—

Hyperpigmentation (focal)

Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019

—

Hypertension (transient)

Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019

—

Pregnancy / OB

Contraindicated

—

Cardiovascular disease

Use caution; transient BP rise

—

Cytotoxicity

—

Concentration-dependent antiproliferative effect observed in vitro; IC50 ~10 mg/mL (argireline, 6-AA analogue)

Commercial formulations typically use 0.05–0.1 mg/mL, well below cytotoxic threshold.

Skin irritation

—

Minimal; well-tolerated in clinical use

Peptide oxidation

—

Methionine residue susceptible to oxidation in formulation; may reduce efficacyKluczyk 2021

Formulation stability issue, not a direct adverse effect.

Systemic absorption

—

Negligible; peptide remains in stratum corneum and epidermisKraeling 2015

Hypersensitivity

—

Rare; no widespread allergic reactions reported

Absolute Contraindications

PT-141

·Uncontrolled hypertension
·Known cardiovascular disease (caution)
·Pregnancy

SNAP-8

·Known hypersensitivity to acetyl octapeptide-3 or formulation excipients

Relative Contraindications

PT-141

·Pre-existing hyperpigmentation disorders
·MC4R-pathway-dependent psychiatric conditions

SNAP-8

·Active skin infections or open wounds at application site
·Neuromuscular disorders (theoretical concern, no documented cases)

05Administration Protocol

Parameter

PT-141

SNAP-8

1. Reconstitution

Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.

Wash face with gentle cleanser and pat dry. Remove makeup and surface oils to optimize peptide contact.

2. Injection site

SQ — abdomen or thigh.

Apply 1–2 drops or pea-sized amount of SNAP-8 serum or cream to target areas (forehead, glabellar lines, crow's feet). Gently massage until absorbed.

3. Timing

≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.

Twice daily — morning and evening. Allow 2–3 minutes for absorption before applying additional skincare products.

4. Storage

Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.

Apply before heavier creams or occlusive moisturizers. Peptides penetrate best from water-based serums on clean skin.

5. Needle

Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.

Store at room temperature, away from direct sunlight. Refrigeration may extend shelf life of formulations containing unstable peptides.

6. Duration

—

Consistent use for 20–60 days required for visible wrinkle reduction. Effects are temporary and reverse upon discontinuation.